GlassScriptPhysician profile
Nedim Cakan
NPI 1417995531
$54,644.64
in general payments reported to CMS, 2019-2025
34 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,913 · 2020: $5,012 · 2021: $669 · 2022: $1,752 · 2023: $21K · 2024: $5,378 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Food and Beverage: $3,770 · Travel and Lodging: $2,795 · Education: $23.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,711.42 |
| Food and Beverage | $3,769.70 |
| Travel and Lodging | $2,795.29 |
| Education | $23.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $38,798.41 | 2023-2025 | |
| Abbvie INC. | $7,071.83 | 2019-2025 | Lupron Depot |
| Tandem Diabetes Care, INC. | $2,237.90 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk As | $1,835.60 | 2019 | |
| Pfizer INC. | $1,450.95 | 2019-2025 | |
| Dexcom, INC. | $456.26 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novo Nordisk INC | $347.77 | 2019-2025 | Sogroya, Wegovy |
| Abbott Laboratories | $321.56 | 2019-2023 | Freestyle Libre 3 |
| Medtronic, INC. | $268.25 | 2021-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $178.95 | 2020-2025 | Gvoke Hypopen |
| Ultragenyx Pharmaceutical INC. | $178.51 | 2019-2023 | |
| Ascendis Pharma Endocrinology INC | $130.76 | 2022-2024 | |
| Tolmar, INC. | $130.04 | 2023-2024 | |
| Insulet Corporation | $127.17 | 2019-2025 | Omnipod |
| Biomarin Pharmaceutical INC. | $115.00 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $108.69 | 2019-2021 | |
| Beta Bionics, INC. | $99.09 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Soleno Therapeutics, INC. | $90.84 | 2025 | Vykat Xr |
| Ipsen Biopharmaceuticals, INC | $67.13 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $64.90 | 2022 | |
| Vistapharm, INC. | $64.04 | 2021 | |
| Azurity Pharmaceuticals, INC. | $58.46 | 2023-2024 | Triptodur, Triptodur |
| Endo Pharmaceuticals INC. | $57.29 | 2019-2022 | |
| Rhythm Pharmaceuticals, INC. | $51.65 | 2021-2023 | Imcivree |
| Neurocrine Biosciences, INC. | $41.06 | 2025 | |
| Medtronic Minimed, INC. | $41.05 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $40.12 | 2019-2023 | Strensiq |
| Kyowa Kirin, INC. | $38.82 | 2023-2024 | Crysvita |
| Amphastar Pharmaceuticals, INC. | $38.82 | 2024-2025 | |
| Lifescan, INC. | $36.07 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $34.33 | 2019-2021 | |
| Embecta Corp. | $26.31 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Catalyst Pharmaceuticals, INC. | $21.05 | 2024 | |
| Ferring Pharmaceuticals INC. | $15.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nedim Cakan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.